Nathan Caffo – President
Nathan Caffo is a life sciences professional whose 20-year industry career has been focused on personalized medicine and applications of genomic technology. Before joining Presage as its first employee in 2009, he consulted for a UK-based diagnostic company, Curidium Medica, and led the efforts to identify an acquirer for that business. Mr. Caffo also led drug in-licensing at Perlegen Sciences, a genomic medicine spin-off of Affymetrix. Prior to that, he worked at Applied Biosystems (now Life Technologies) and its sister company Celera (now Quest Diagnostics) for 11 years in a number of technical and business roles, including managing the company’s genomics service business. Mr. Caffo has a B.S. in Microbiology from Pennsylvania State University.
Richard Klinghoffer, Ph.D. – Chief Scientific Officer
Richard Klinghoffer brings 20 years of research, drug development and team leadership experience to Presage. His team established the Presage platform, CIVO™, which enables multiplexed drug efficacy studies in both in vivo preclinical models of cancer and the human oncology clinic. Before joining Presage, Dr. Klinghoffer worked in both small biotech and large pharma settings, most recently at Merck’s Rosetta Inpharmatics. At Rosetta, he led a team of scientists focused on identifying and validating cancer targets and predictive biomarkers of novel chemotherapeutics for Merck’s Oncology Franchise. Dr. Klinghoffer earned his Ph.D. from the University of Colorado Health Sciences Center and was a Special Fellow of the Leukemia and Lymphoma Society as a Postdoctoral Fellow at the Fred Hutchinson Cancer Research Center.